share_log

U.K. National Institute for Health and Care Excellence Approves BeiGene's BRUKINSA As Rare Lymphoma Treatment

U.K. National Institute for Health and Care Excellence Approves BeiGene's BRUKINSA As Rare Lymphoma Treatment

英國國家健康與護理卓越研究所批准百濟神州的BRUKINSA作為罕見淋巴瘤的治療
MT Newswires ·  2022/09/20 02:14

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論